Welcome to our dedicated page for Pharmacyte Biotech news (Ticker: PMCB), a resource for investors and traders seeking the latest updates and insights on Pharmacyte Biotech stock.
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) generates news that spans biotechnology development, strategic investments, and corporate finance. The company has reported on its ongoing evaluation of the Cell-in-a-Box live-cell encapsulation technology for potential use in cancer, diabetes, and malignant ascites, as well as its plans to engage with the U.S. Food and Drug Administration for guidance on future development steps.
Recent press releases highlight PharmaCyte’s shift toward using its cash and marketable securities to support external opportunities. The company has announced a $5 million stake in Femasys Inc., a women’s health-focused biomedical company, and a $7 million strategic investment in MyMD Pharmaceuticals, Inc., which is developing therapies for age-related diseases and inflammatory and autoimmune conditions. PharmaCyte has also disclosed an increased investment in TNF Pharmaceuticals (later referenced as Q/C Technologies, Inc.) through preferred stock and warrants tied to a licensed light-based processing accelerator platform intended for compute-intensive applications.
Investors following PMCB news will also see updates on capital structure and balance sheet actions, including a cash tender offer to repurchase a substantial portion of its outstanding common stock, a private placement of convertible redeemable preferred stock and warrants that raised approximately $35 million, and a subsequent Series C convertible preferred stock financing with accompanying warrants. Company communications emphasize what management describes as a disciplined capital allocation strategy and efforts to strengthen its financial position.
This news page aggregates PharmaCyte’s announcements about technology evaluation, strategic investments, tender offers, preferred stock and warrant financings, and related stockholder and governance matters, providing a single stream of company-issued updates for PMCB shareholders and observers.
PharmaCyte Biotech (Nasdaq:PMCB) announced it has successfully monetized its stake in Femasys (Nasdaq:FEMY), boosting its liquidity position.
Proceeds lift cash and marketable securities to approximately $20 million in cash (up from $13.3 million on July 31, 2025) and the company reports roughly $25 million in marketable securities as valued in its most recent 10-Q.
The company noted a recent share price of $0.65 with about 6.8 million shares outstanding and reiterated plans to pursue value-accretive investments and disciplined operations to enhance shareholder returns.
PharmaCyte Biotech (Nasdaq:PMCB) has increased its investment in TNF Pharmaceuticals (Nasdaq:TNFA) by $3 million to support TNF's recent licensing agreement with LightSolver. The investment backs LightSolver's revolutionary processing accelerator technology, which uses light for computation to achieve 90% energy reduction while delivering superior performance compared to conventional computing methods.
The technology is planned for cryptocurrency mining and blockchain applications. TNF plans to change its name and ticker symbol to align with this new strategic direction. PharmaCyte maintains a strong financial position with total assets exceeding $55 million as of April 30, 2025, and continues to explore additional investment opportunities.
PharmaCyte Biotech (Nasdaq:PMCB) has successfully closed a $7 million financing. The company's financial position shows approximately $15.5 million in cash and over $30 million in securities as of April 30, 2025. With this new financing, PharmaCyte aims to strengthen its balance sheet and support ongoing business initiatives.
The company, under Interim CEO Josh Silverman's leadership, maintains a reduced operational burn rate and plans to use the capital to advance initiatives and evaluate strategic opportunities. Currently, PharmaCyte has approximately 6.8 million shares of common stock outstanding.
PharmaCyte Biotech (Nasdaq:PMCB) has secured a $7 million private placement from existing investors through the sale of Series C convertible preferred stock. The financing includes 7,000 shares of preferred stock at $1,000 per share, convertible into 7 million common shares, along with warrants to purchase an additional 7 million shares.
The preferred stock features a $1.00 conversion price and a 7.0% quarterly cash dividend. The warrants are immediately exercisable at $1.00 per share with a five-year term. The transaction, expected to close around August 19, 2025, was priced at a premium to the current market price and will be conducted as a private placement through GP Nurmenkari Inc.
MyMD Pharmaceuticals has secured up to $42 million in strategic investments through two private placement funding rounds. The first round raised $7 million from PharmaCyte Biotech, while the second round secured another $7 million from existing shareholders. These financings involve Series G and Series F-1 Preferred Stock, both convertible to MYMD common stock, with accompanying warrants. The closings are anticipated around May 22, 2024. The Series G Preferred Stock includes 7,000 shares with a $1,000 per share value, and Series F-1 includes 5,050 shares. The funds are expected to support MyMD's clinical studies on MYMD-1 for sarcopenia over the next two years. The full conversion and warrant exercise are subject to stockholder approval.
PharmaCyte Biotech has announced a $7 million strategic investment in MyMD Pharmaceuticals, a company focused on treating inflammatory diseases, age-related conditions, and autoimmune disorders. This investment is part of PharmaCyte's strategy to leverage its $65 million cash position to enhance stockholder value. MyMD's lead product, MYMD-1, has shown promising results in a Phase 2 clinical trial for sarcopenia, and the company plans to move forward with further clinical studies in collaboration with the FDA. Both companies express optimism about the potential for future collaboration and the benefits of combining their expertise and resources.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Pharmacyte Biotech (PMCB)?
What is the market cap of Pharmacyte Biotech (PMCB)?
